Vertex Pharmaceuticals has secured an important expansion of access to its gene-editing therapy Casgevy, opening a new treatment option for eligible children aged five and over with severe sickle cell disease or transfusion-dependent beta thalassaemia. The decision strengthens the company’s position in the advanced therapies market while extending the reach of a treatment first authorised in the UK in 2023.

The Medicines and Healthcare products Regulatory Agency (MHRA) granted the extended marketing authorisation on 29 October 2026, allowing Casgevy to be used in eligible younger patients who were previously outside its approved age range. The regulator confirmed the decision in its 30 October announcement. The treatment, known scientifically as exagamglogene autotemcel, was previously authorised for patients aged 12 and over.

The development also advances the treatment’s NHS market access. Updated NICE guidance and a managed-access agreement support access for eligible younger patients in England, alongside a reimbursement agreement with NHS England. Vertex is also working with health authorities in Wales, Scotland and Northern Ireland to extend access, creating further opportunities for the therapy to reach eligible patients across the UK.

Casgevy uses CRISPR/Cas9 gene editing to modify a patient's own blood stem cells, enabling the production of functioning haemoglobin. The cells are collected, edited in a specialist laboratory and infused back into the patient following conditioning treatment. This highly specialised process demonstrates the clinical and manufacturing complexity behind advanced cell and gene therapies. The MHRA's regulatory information outlines the treatment process and the continued monitoring required for its safety and effectiveness.

For Vertex, the extension builds on an established relationship with the UK health system and supports the commercial development of Casgevy in a growing advanced-therapy market. The company reported $99 million in global Casgevy revenue in the third quarter of 2026, highlighting the treatment's increasing contribution to its portfolio. Its third-quarter financial results also detail its international regulatory progress.

For the sector, the lesson is direct: expanding access to advanced therapies depends on more than scientific innovation. Regulatory approval, reimbursement agreements and specialist treatment pathways must work together to bring complex medicines to eligible patients, creating new opportunities for pharmaceutical development and healthcare delivery.

Source: PharmaTimes / MHRA / NICE / Vertex Pharmaceuticals